Global EMEA Point-Of-Care Diagnostics Market Size Study, by Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), by End-use (Clinics, Home), and Regional Forecasts 2022-2032

Global EMEA Point-Of-Care Diagnostics Market Size Study, by Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), by End-use (Clinics, Home), and Regional Forecasts 2022-2032

The Global EMEA Point-Of-Care Diagnostics Market is valued at approximately USD 13 billion in 2023 and is anticipated to grow at a steady CAGR of 6.20% during the forecast period 2024-2032.Point-of-care (POC) diagnostics are revolutionizing the medical landscape by providing rapid, on-site diagnostic results, empowering clinicians to make timely decisions, and improving patient outcomes. This technology spans various applications, including glucose monitoring, infectious disease detection, cancer marker identification, and coagulation testing. Its adoption is driven by the increasing demand for accessible, efficient healthcare solutions in clinics and home settings.

The market is propelled by the growing prevalence of chronic diseases, such as diabetes and cardiovascular disorders, which necessitate continuous monitoring and swift interventions. The proliferation of advanced technologies like microfluidics and biosensors has enhanced the accuracy and usability of POC devices, making them indispensable in both professional and home care environments. Furthermore, the increasing shift towards decentralized healthcare systems, supported by robust advancements in diagnostic capabilities, has amplified the demand for portable and user-friendly diagnostic tools.

However, challenges like high costs associated with advanced POC devices and limited awareness in developing regions could hamper growth. Nevertheless, the expanding focus on healthcare accessibility and the growing integration of IoT-enabled POC devices for real-time data tracking and remote monitoring are poised to create lucrative growth opportunities. The emergence of minimally invasive testing technologies is further enhancing patient compliance and driving innovation in the sector.

Regionally, Europe dominates the market, owing to its advanced healthcare infrastructure, high prevalence of chronic diseases, and favorable government initiatives supporting diagnostic advancements. The Middle East & Africa region is also witnessing significant growth, driven by increasing healthcare investments and improving access to medical technologies. Emerging markets in the EMEA region are adopting POC diagnostics to bridge healthcare gaps, particularly in rural and underserved areas.

Major market players included in this report are:
• Abbott Laboratories
• Siemens Healthineers AG
• Roche Diagnostics
• Danaher Corporation
• QuidelOrtho Corporation
• bioMérieux SA
• Becton, Dickinson and Company
• Sysmex Corporation
• Hologic, Inc.
• Thermo Fisher Scientific Inc.
• Nova Biomedical
• Bio-Rad Laboratories, Inc.
• Chembio Diagnostics, Inc.
• EKF Diagnostics Holdings plc
• OraSure Technologies, Inc.

The detailed segments and sub-segments of the market are explained below:

By Product:
• Glucose Testing
• Cancer Marker
• Coagulation Testing
• Infectious Disease

By End-use:
• Clinics
• Home

By Region:

Europe:
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Middle East & Africa:
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Comprehensive forecasts from 2022-2032, covering market segmentation and regional dynamics.
• Strategic insights for stakeholders to leverage growth opportunities.
• Analysis of the competitive landscape with key player strategies and innovations.
• In-depth exploration of market drivers, challenges, and opportunities.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.